SomnoMed share price rises after reporting positive earnings

The SomnoMed Limited (ASX: SOM) share price has risen today after the company reported its half-year earnings.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Somnomed Limited (ASX: SOM) share price has spiked today after the sleep treatment company reported its earnings to the ASX for the six months to December 31, 2019 (1H20).

Somnomed is a medical company specialising in the treatment of patients suffering from sleep-related disorders such as obstructive sleep apnoea, which the company notes affects up to 9% of women and 25% of men globally. It has over 545,000 patients worldwide and a market capitalisation of $211 million on current prices.

SOM shares closed at $3.30 yesterday but opened at $3.33 this morning and is trending higher since, going for $3.36 at the time of writing – a rise of 2.13%. Earlier this morning, Somnomed's share price touched $3.37, which was a new 52-week high for the company. The Somnomed share price has now risen 106% in the past year.

What did SomnoMed announce today?

Pleasingly for the company, Somnomed announced a 15% increase in revenues to $33.256 million for 1H20, up from 1H19's $28.815 million.

Revenue growth was strongest in the North America region, which saw a 26% increase. European sales saw a 10% rise while the APAC (Asia Pacific, including Australia) region saw an 11% bump.

Earnings before Interest, Tax, Depreciation and Amortisation (EBITDA) came in at $3 million, which is a 130% increase on 1H19's $1.3 million.

Compared with the previous six months (to June 30, 2019), the company has seen its Total Assets rise from $34.8 million to $42.7 million, while Total Liabilities has also increased from $16.9 million to $22.6 million – translating into Net Assets of $20.1 million (up from $17.8 million).

The company (in continuing with its policy in prior years) did not pay a dividend during the period.

Outlook for 2020

Somnomed has reiterated its guidance for FY20, for which it estimates revenues to come in the $67-$69 million range and earnings in the $6.3-$6.7 million range. There is no notice nor indication the payment of a dividend in FY20 will occur.

The company notes that it has nearly 550,000 patients and yet the global addressable market for obstructive sleep apnoea is estimated at roughly 1.36 billion people, with 54 million in the United States of America alone and a further 49 million across France and Germany.

Somnomed is hoping that this large addressable market will provide fertile ground for its new SomnoDent Avant product, which it hopes will prove to be a more comfortable and effective treatment solution for obstructive sleep apnoea.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Woman in celebratory fist move looking at phone
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A female financial services professional with a manicured black afro hairstyle turns an ipad screen to show a client across the table a set of ASX shares figures in graph format.
Share Market News

Record CBA share price and blockbuster merger push ASX 200 financials sector to the top

ASX financial stocks led the 11 market sectors last week with a 1.95% gain.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Share Market News

CBA Shares in focus: How Australia's most valuable company is using AI to compete

Could AI initiatives drive CBA shares higher?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Broker Notes

These ASX 200 shares could rise 20% to 50%

Looking for big returns? Brokers think these shares could do the job.

Read more »

asx share price represented by cartoon letters spelling the word FOMO
Share Market News

What did Macquarie's "FOMO Meter" reveal about the stock market in May?

Is the market getting frothy or is there still room to climb?

Read more »

Market up or down
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the week...

Read more »

Man in an office celebrates at he crosses a finish line before his colleagues.
Share Gainers

4 ASX 200 shares racing ahead of the benchmark this week

ASX investors sent these four stocks soaring 12% to 18% this week. But why?

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »